Evidence map›Paper›PMID 41279002›Full record

ArticlebioRxiv : the preprint server for biology2025

Novel, small molecules targeting the 5-HT

Rebecca Ravenelle, Shi-Xian Deng, Mel Nelson, Maria H Pedersen, Indira Mendez-David, Denis J David, Victor M Luna, Gergely Turi, Madeline Abramson, Jonathan A Javitch and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rebecca RavenelleDivision of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, NY, USA.ORCID 0000-0001-9811-9760
Shi-Xian DengDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Mel NelsonDepartment of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA.
Maria H PedersenDepartment of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA.
Indira Mendez-DavidUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri MOISSAN, Orsay, France.
Denis J DavidUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri MOISSAN, Orsay, France.
Victor M LunaAlzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Gergely TuriDivision of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, NY, USA.
Madeline AbramsonDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA.
Jonathan A JavitchDepartment of Psychiatry, Columbia University Irving Medical Center (CUIMC), New York, NY, 10032, USA.
Donald W LandryDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Briana K ChenDivision of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, NY, USA.
Christine A DennyDivision of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc. (RFMH)/New York State Psychiatric Institute (NYSPI), New York, NY, USA.ORCID 0000-0002-6926-2020

Funding

Research Training in Late-Life NeuroPsychiatric DisordersT32MH020004 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Patrick J Brown · 1998 to 2026
$6.1M
NIMH NIH HHS T32 MH020004
6 · The paper itself

Abstract

backgroundStress is a risk factor for developing psychiatric disorders, including major depressive disorder (MDD). Compounds targeting the serotonin type 4 receptor (5-HT

methodsThree 5-HT

resultsProphylactic administration of DL5, DL7, or DL8 was effective at reducing stress-induced maladaptive behaviors in male and female mice; DL7 and DL8 were effective when administered after stress. When administered following learned helplessness (LH), DL7 reduced behavioral despair and increased c-Fos in the dentate gyrus (DG) and CA3. All novel compounds attenuated large-amplitude AMPA receptor-mediated bursts in ventral CA3 (vCA3). In aged male mice, prophylactic DL7 reduced behavioral despair.

conclusionsThese results characterize novel 5-HT

Indexed as

anxietyfearhippocampushyponeophagiamemoryserotonin

Identifiers

PMID41279002
PMCPMC12632445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.